Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Back to the future: antibody-based strategies for the treatment of infectious diseases.

Literature DB >> 12102547

Back to the future: antibody-based strategies for the treatment of infectious diseases.

H Barbaros Oral¹, Cüneyt Ozakin, Cezmi A Akdiş.

Abstract

Before antibiotics, sera from immune animals and humans were used to treat a variety of infectious diseases, often with successful results. After the discovery of antimicrobial agents, serum therapy for bacterial infections was rapidly forsaken. In the last two decades, problems with treatment of newly emerged, re-emerged, or persistent infectious diseases necessitated researchers to develop new and/or improved antibody-based therapeutic approaches. This article reviews some information on the use of antibodies for the treatment of infectious diseases, with special reference to the most seminal discoveries and current advances as well as available treatment approaches in this field.

Entities: Disease Species

Mesh：

Substances：

Year: 2002 PMID： 12102547 DOI： 10.1385/MB:21:3:225

Source DB: PubMed Journal: Mol Biotechnol ISSN： 1073-6085 Impact factor: 2.695

98 in total

1. Intracellular neutralization of virus by immunoglobulin A antibodies.

Authors: M B Mazanec; C S Kaetzel; M E Lamm; D Fletcher; J G Nedrud
Journal: Proc Natl Acad Sci U S A Date: 1992-08-01 Impact factor: 11.205

Review 2. Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases.

Authors: R M Krause; N J Dimmock; D M Morens
Journal: J Infect Dis Date: 1997-09 Impact factor: 5.226

3. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections.

Authors: H Basma; A Norrby-Teglund; A McGeer; D E Low; O El-Ahmedy; J B Dale; B Schwartz; M Kotb
Journal: Infect Immun Date: 1998-05 Impact factor: 3.441

4. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.

Authors: K N Subramanian; L E Weisman; T Rhodes; R Ariagno; P J Sánchez; J Steichen; L B Givner; T L Jennings; F H Top; D Carlin; E Connor
Journal: Pediatr Infect Dis J Date: 1998-02 Impact factor: 2.129

5. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.

Authors: H F Starnes; M K Pearce; A Tewari; J H Yim; J C Zou; J S Abrams
Journal: J Immunol Date: 1990-12-15 Impact factor: 5.422

6. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

Authors: R V McCloskey; R C Straube; C Sanders; S M Smith; C R Smith
Journal: Ann Intern Med Date: 1994-07-01 Impact factor: 25.391

7. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial.

Authors: D R Snydman; B G Werner; N N Dougherty; J Griffith; R H Rubin; J L Dienstag; R H Rohrer; R Freeman; R Jenkins; W D Lewis; S Hammer; E O'Rourke; G F Grady; K Fawaz; M M Kaplan; M A Hoffman; A T Katz; M Doran
Journal: Ann Intern Med Date: 1993-11-15 Impact factor: 25.391

8. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120.

Authors: H F Günthard; P L Gowland; J Schüpbach; M S Fung; J Böni; R S Liou; N T Chang; P Grob; P Graepel; D G Braun
Journal: J Infect Dis Date: 1994-12 Impact factor: 5.226

Back to the future: antibody-based strategies for the treatment of infectious diseases.

1. Intracellular neutralization of virus by immunoglobulin A antibodies.

Review 2. Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases.

3. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections.

4. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.

5. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.

6. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

7. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial.

8. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120.

Review 9. Antibody-based therapies for emerging infectious diseases.

10. Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization.

1. A reaction-diffusion model of the receptor-toxin-antibody interaction.

Review 2. Antibodies: an alternative for antibiotics?

3. A simple model for assessment of anti-toxin antibodies.

Review 4. Exploring the native human antibody repertoire to create antiviral therapeutics.